TEMENOS
12.5.2021 08:32:06 CEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that 10,000 business leaders and technologists will come together on 26 - 27 May at TCF Online 2021 , the flagship event in banking. The two-day interactive, online-only event will feature keynotes from PayPal, Barclays and Varo, plus over 50 live and on-demand sessions and 50 industry speakers inspired by a shared mission to make banking better, together. Register for this free to attend event.
Powered by new technologies such as Cloud, AI and SaaS, banks of all sizes can deliver customer experiences that are better, faster and smarter. They can also achieve hyper-efficient cost models to deliver more value to their customers and leverage open ecosystems to enhance and extend their offering. At TCF Online 2021, Temenos will unveil game-changing innovations enabling banks to simplify their operations, innovate and collaborate at speed and digitally transform faster than ever before.
At TCF Online 2021, attendees from over 150 countries will also hear from some of the most influential industry experts in the financial sector, including:
- Ryan Prichard, VP, CTO of Global Credit, PayPal , on the latest innovations in payments, including how PayPal is disrupting the market with its new buy now, pay later product enabled by Temenos technology.
- Ashok Vaswani, CEO of Consumer Banking and Payments, Barclays, on the importance of banks being purpose-led and playing a greater role in the economy and society in a post-pandemic world.
- Colin Walsh, Founder and CEO, Varo , a year on after making history as the first fintech in the U.S. to obtain a national banking license, on making banking more accessible and inclusive for all.
- Jim Marous, co-publisher of The Financial Brand and top 100 influencer, on how banks can humanize their customer experience in a digital world and joining him on the virtual stage, Chris Parker, Co-CEO of Partners Federal Credit Union.
- Eric Purdum, General Manager, DXC on its collaboration with Temenos and accelerating the digital transformation for large tier-1 banks.
- David Hornery, Co-CEO and Co-Founder, Judo, on the future for challenger banks and Judo’s unique approach to the SME market in Australia.
- Barri Maggott, CEO, Curo Fund Services, on the digital transformation journey in funds administration.
- And Max Chuard, CEO of Temenos, on the once-in-a-generation opportunity digital presents for banking, unveiling Temenos’ latest innovations in cloud and AI that will propel the industry forward.
Max Chuard, CEO, Temenos, said: “The urgency for change in banking has never been greater. Consumers and business customers demand and expect fast, frictionless, personalized experiences. Covid-19 has accelerated the trend towards digital banking and new technologies such as Cloud, AI and SaaS make the business case for transformation compelling. Yet while challengers are innovating and launching rapidly on modern technology stacks, legacy systems are still holding banks back. Temenos technology gives all banks the freedom, agility and speed to innovate and adapt to changing customer behavior, business and regulatory change. At TCF Online 2021, our community of thousands will hear about the latest innovations and how together we will make banking better.”
TCF Online brings the key announcements, customer insights and latest software demonstrations from Temenos. To register for this free-to-attend event, visit www.temenos.com/events/tcf-online-2021 .
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005935/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom